REFERENCES
1. Andre, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., ...
& Spielmann, M. (2004). Breast cancer with synchronous metastases: trends
in survival during a 14-year period.
Journal of Clinical Oncology
,
22
(16),
3302-3308.
2. Gennari, A., Conte, P., Rosso, R., Orlandini, C., & Bruzzi, P. (2005). Survival
of metastatic breast carcinoma patients over a 20
‐
year period.
Cancer
,
104
(8), 1742-1750.
3. Largillier, R., Ferrero, J. M., Doyen, J., Barriere, J., Namer, M., Mari, V., ... &
Chamorey, E. (2008). Prognostic factors in 1038 women with metastatic
breast cancer.
Annals of Oncology
, mdn424.
4. Harris, J. R., Lippman, M. E., Osborne, C. K., & Morrow, M. (2012).
Diseases of the Breast
. Lippincott Williams & Wilkins.
5. Chang, J., Clark, G. M., Allred, D. C., Mohsin, S., Chamness, G., & Elledge,
R. M. (2003). Survival of patients with metastatic breast carcinoma.
Cancer
,
97
(3), 545-553.
6. Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., ... &
Cardoso, M. J. (2014). ESO-ESMO 2nd international consensus guidelines for
advanced breast cancer (ABC2). The Breast, 23(5), 489-502.
7. Pagani, O., Senkus, E., Wood, W., Colleoni, M., Cufer, T., Kyriakides, S., ...
& Cardoso, F. (2010). International guidelines for management of metastatic
breast cancer: can metastatic breast cancer be cured?.
Journal of the
National Cancer Institute
,
102
(7), 456-463.
8. Palmieri, C., Krell, J., James, C. R., Harper-Wynne, C., Misra, V., Cleator, S.,
& Miles, D. (2010). Rechallenging with anthracyclines and taxanes in
metastatic breast cancer.
Nature Reviews Clinical Oncology
,
7
(10), 561-574.
9. Musgrove, E. A., & Sutherland, R. L. (2009). Biological determinants of
endocrine resistance in breast cancer.
Nature Reviews Cancer
,
9
(9), 631-
643.
